Features of clinic and therapy of combined dermatoses in patients with a comorbid background

The article discusses the causes of occurrence and the clinical features of chronic dermatoses complicated by mycotic infections, which occur in patients with comorbid backgrounds. It presents data from domestic and international literature on the epidemiology and characteristics of the course of combined dermatoses. Recent scientific studies indicate obesity and metabolic syndrome as aggravating factors in the progression of psoriasis, allergodermatoses, and mycoses. The accompanying somatic problems worsen the course of skin diseases, contribute to their chronicity, hinder effective diagnosis and treatment, reduce patients’ quality of life, and may lead to an unfavorable prognosis. At the same time, a patient with metabolic syndrome may simultaneously present several skin conditions, each influencing the course of the others, which exacerbates the clinical picture and increases the severity of the disease. Warm, moist environments and friction in skin folds promote colonization of eruptions in psoriasis and allergodermatoses by bacteria, fungi, or pathogenic yeasts, leading to eczematization with exudation and erosion formation, often resistant to therapy. Particular emphasis is placed on the diagnosis and treatment of this group of patients, as fold lesions pose difficulties, especially against the background of comorbidities. Effective treatment requires a comprehensive assessment of clinical manifestations and the presence of accompanying diseases to prescribe combination therapies, as well as preventive measures to reduce the risk of secondary infections. The article also includes our clinical observations of patients with a comorbid background (obesity, diabetes mellitus) suffering from chronic dermatoses complicated by mycotic infections. It is demonstrated that the use of Akriderm GK cream (0.05% clotrimazole + 0.1% gentamicin + 1% betamethasone) and Acrimicole cream (2% sertaconazole cream) achieves a positive effect in treating dermatitis complicated by fungal infections in the context of comorbidities.

1. Sharabchiev YuT, Antipov VV, Antipova SI. Comorbidity is an actual scientific and practical problem of the 21st century medicine. Meditsinskie Novosti. 2014;(8):6–11. (In Russ.) Available at: https://www.mednovosti.by/Journal.aspx?id=297.

2. Tlish MM, Kuznetsova TG, Naatyzh ZhYu. The polymorbidity in dermatology: late diagnosis and consequences. Lechaschi Vrach. 2019;(7):76–79. (In Russ.) Available at: https://journal.lvrach.ru/jour/article/view/346/344.

3. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017;76(3):393–403. https://doi.org/10.1016/j.jaad.2016.07.065.

4. Qureshi A, Friedman A. Comorbidities in Dermatology: What’s Real and What’s Not. Dermatol Clin. 2019;37(1):65–71. https://doi.org/10.1016/j.det.2018.07.007.

5. Martinez-Rossi NM, Peres NTA, Bitencourt TA, Martins MP, Rossi A. State-ofthe-Art Dermatophyte Infections: Epidemiology Aspects, Pathophysiology, and Resistance Mechanisms. J Fungi. 2021;7(8):629. https://doi.org/10.3390/jcf7080629.

6. Svirshchevskaya EV, Matushevskaya EV, Ivanova MA, Vladimirova EV, Matushevskaya YI. Epidemiology, therapy and prevention of superficial skin mycoses. Meditsinskiy Sovet. 2024;(5):222–228. (In Russ.) https://doi.org/10.21518/ms2024-156.

7. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. https://doi.org/10.1016/j.jaad.2016.07.064.

8. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–662. https://doi.org/10.1016/j.jaad.2012.08.015.

9. Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and metaanalysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77(4):657–666.e8. https://doi.org/10.1016/j.jaad.2017.04.1133.

10. Leskova IV, Ershova EV, Nikitina EA, Krasnikovsky VYa, Ershova YuA, Adamskaya LV. Obesity in Russia: modern view in the light of a social problems. Obesity and Metabolism. 2019;16(1):20–26. (In Russ.) https://doi.org/10.14341/omet9988.

11. Akimov VG. Rare and atypical manifestations of vulgar psoriasis. Сonsilium Medicum. Dermatology (Suppl.). 2013;(2-3):4–7. (In Russ.) Available at: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2013/derma2013_pril%20/derma2013_2_3_pril/redkiei-atipichnye-proyavleniya-vulgarnogo-psoriaza.

12. Jagielski T, Rup E, Ziółkowska A, Roeske K, Macura AB, Bielecki J. Distribution of Malassezia species on the skin of patients with atopic dermatitis, psoriasis, and healthy volunteers assessed by conventional and molecular identification methods. BMC Dermatol. 2014;14:3. https://doi.org/10.1186/1471-5945-14-3.

13. Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. Dermatology. 2012;225(2):121–126. https://doi.org/10.1159/000342180.

14. Khismatullina ZR, Amineva AM, Kurochkin DP, Gareeva DF, Zagidullin NS. Psoriasis, psoriatic arthritis, metabolic disorders and cardiovascular disease. What is commons? Klinicheskaya Dermatologiya i Venerologiya. 2020;19(2):139–147. (In Russ.) https://doi.org/10.17116/klinderma202019021139.

15. Лыкова СГ, Моржанаева МА, Немчанинова ОБ, Свечникова ЕВ. Псориаз у пациентов с метаболическим синдромом: клинические аспекты проблемы. Клиническая дерматология и венерология. 2020;19(2):214–222. https://doi.org/10.17116/klinderma202019021214.

16. Lykova SG, Morzhanaeva MA, Nemchaninova OB, Svechnikova EV. Psoriasis in patients with metabolic syndrome: clinical aspects of the problem. Klinicheskaya Dermatologiya i Venerologiya. 2020;19(2):214–222. (In Russ.) https://doi.org/10.17116/klinderma202019021214.

17. Бутов ЮС, Скрипкин ЮК, Иванов ОЛ. (ред.). Дерматовенерология. М.: ГЭОТАР Медиа; 2020. 896 c. Режим доступа: https://library.mededtech.ru/rest/documents/ISBN9785970457085/.

18. Koçinaj AF, Kotori MG, Koraqi A, Fida M. Dermatomycosis frequency and localization sites. Med Arch. 2015;69(1):58–59. https://doi.org/10.5455/medarh.2015.69.58-59.

19. Silina LV. Algorithms for topical therapy of mycoses at the daily appointment of a dermatologist. Meditsinskiy Sovet. 2024;18(14):7–12. (In Russ.) https://doi.org/10.21518/ms2024-284.

20. Pankratov VG. Dermatomycoses in practice of primary level physician. Healthcare (Minsk). 2013;(4):39–45. (In Russ.) Available at: https://www.elibrary.ru/pyzcsf.

21. Khaldin AA, Sergeev VU, Izumova IM. Present views of inguinal dermatophytoses: etiology, epidemiology, clinical presentation, and effective therapy. Klinicheskaya Dermatologiya i Venerologiya. 2005;(4):135–141. (In Russ.) Available at: https://www.elibrary.ru/opeoon.

22. Разнатовский КИ, Котрехова ЛП. Микозы кожи и ногтей. М.: ГЭОТАР-Медиа; 2020. 232 с. Режим доступа: https://www.geotar.ru/lots/NF0017583.html.

23. Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. 2023. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/234_2.

24. Syed ZU, Khachemoune A. Inverse psoriasis: case presentation and review. Am J Clin Dermatol. 2011;12(2):143–146. https://doi.org/10.2165/11532060-000000000-00000.

25. Khlebnikova AN. Inverse psoriasis: the diagnostic value of dermatoscopic assessment and the experience of treatment with a combination topical agent (a clinical series). Almanac of Clinical Medicine. 2022;50(7):447–454. (In Russ.) https://doi.org/10.18786/2072-0505-2022-50-032.

26. Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int. 2013;62(2):151–161. https://doi.org/10.2332/allergolint.13-RAI-0564.

27. Matushevskaya EV, Svirshchevskaya EV, Ertneeva IYa. Clinico-immunologic indices in patients with atopic dermatitis over treatment with akriderm preparations. Klinicheskaya Dermatologiya i Venerologiya. 2008;(5):39–44. (In Russ.) Available at: http://elib.fesmu.ru/Article.aspx?id=191944.

28. Miedzobrodzki J, Kaszycki P, Bialecka A, Kasprowicz A. Proteolytic activity of Staphylococcus aureus strains isolated from the colonized skin of patients with acute-phase atopic dermatitis. Eur J Clin Microbiol Infect Dis. 2002;21(4):269–276. https://doi.org/10.1007/s10096-002-0706-4.

29. Potekayev NN, Sherina TF. To the association of dermatoses and mycoses of the skin. Russian Journal of Skin and Venereal Diseases. 2004;(6):55–57. (In Russ.) Available at: https://www.elibrary.ru/opkash.

30. Belousova TA, Goryachkina MV. Аlgorithm for external treatment of dermatoses of mixed etiology. Pharmacotherapy in Dermatovenerology. 2011;(5):146–152. (In Russ.) Available at: https://medi.ru/info/17.

31. Ключарева СВ. Результаты сравнительного исследования косметической линии Айсида и стандартных схем терапии у пациентов с чувствительной кожей и хроническими дерматозами. М.; 2010. 58 с.

32. Sokolova TV, Grigoryan SR. Microbial eczema: choosing a treatment regimen. Vrach. 2007;(3):36–42. (In Russ.) Available at: https://www.elibrary.ru/kxxvtd.

33. Shishkova VN. Features of the development of dermatological manifestations in patients with type 2 diabetes and/or metabolic syndrome. Consilium Medicum. Dermatology (Suppl.). 2015;(3):37–40. (In Russ.) Available at: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2015/derma2015_pril/derma2015_3_pril/osobennosti-razvitiya-dermatologicheskikh-proyavleniy-u-patsientovs-sakharnym-diabetom-tipa-2-i-ili.

34. Gupta AK, Konnikov N, MacDonald P, Rich P, Rodger NW, Edmonds MW et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol. 1998;139(4):665–671. https://doi.org/10.1046/j.1365-2133.1998.02464.x.

35. Martynova MI, Petryaikina EE, Pilyutik VF. Features of skin disorders in insulin-dependent diabetes mellitus. Lechaschi Vrach. 2002;(6):32–37. (In Russ.) Available at: https://www.lvrach.ru/2000/08/4526235.

36. Burova SA. Treatment of onychomycosis in patients with diabetes mellitus or glucose intolerance. Vestnik Dermatologii i Venerologii. 2005;(6):55–57. (In Russ.) Available at: https://www.elibrary.ru/ilfxjn.

37. Loya-Acosta J, Guzmán-Ochoa TC, Tirado-Sánchez A. Torres-Camacho P, Díaz-Molina V, Bonifaz A. Candidal Intertrigo: Underdiagnosed Entity. Curr Fungal Infect Rep. 2025;19. https://doi.org/10.1007/s12281-025-00511-0.

38. Об утверждении стандарта медицинской помощи взрослым при экземе (диагностика, лечение и диспансерное наблюдение). Приказ Министерства здравоохранения РФ от 8 апреля 2022 г. №241н. Режим доступа: https://okvd38.gosuslugi.ru/netcat_files/35/68/Ekzema_vzroslye_.pdf?ysclid=mi5qrlicl9801920790.

39. Gerasimchuk EV. Acriderm-GK cream, as a remedy for the treatment of mixed skin infections. Klinicheskaya Dermatologiya i Venerologiya. 2005;(4):142–146. (In Russ.)

40. Kungurov NV, Kokhan MM, Keniksfest YuV, Kascheeva YaV, Letaeva OV, Kuklin IA, Stukova EI. Innovative combined topical remedy in the treatment of complicated dermatoses: experience of the application. Lechaschi Vrach. 2019;(5):38. (In Russ.) Available at: https://journal.lvrach.ru/jour/article/view/377/375.

41. Khamaganova IV, Kashevarov DF, Malyaremko EN, Maximova MV. Sertaconazole administration in outpatient practice. RMJ. 2018;26(8-2): 87–91. (In Russ.) Available at: https://www.rmj.ru/articles/dermatologiya/Primenenie_sertakonazola_v_ambulatornoy_praktike.

42. Barnes TM, Mijaljica D, Townley JP, Spada F, Harrison IP. Vehicles for Drug Delivery and Cosmetic Moisturizers: Review and Comparison. Pharmaceutics. 2021;13(12):2012. https://doi.org/10.3390/pharmaceutics13122012.

43. Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Tinea versicolor: an updated review. Drugs Context. 2022;11:2022-9-2. https://doi.org/10.7573/dic.2022-9-2.

44. Goriachkina MV, Belousova TA, Potekaev NN. Sertaconazole in the topical treatment of superficial skin mycoses. Klinicheskaya Dermatologiya i Venerologiya. 2012;10(5):46–51. (In Russ.) Available at: https://www.mediasphera.ru/issues/klinicheskaya-dermatologiyai-venerologiya/2012/5/downloads/ru/031997-2849201259.

45. Fadeev IE, Poletova TN, Mass EE. Local antifungal drug sertaconazole: a reserve antimycotic or a first-line medication of empirical therapy for vulvovaginitis? Consilium Medicum. 2019;21(6):73–76. (In Russ.) https://doi.org/10.26442/20751753.2019.6.19055.

46. Kruglova LS, Mayorov RYu. Mycoses of the skin: Issues of effective therapy. Medical Alphabet. 2022;(27):24–28. (In Russ.) https://doi.org/10.33667/2078-5631-2022-27-24-28.

47. Yelinov NP, Vasilyeva NV, Raznatovsky IK. Dermatomycoses, or superficial mycoses of skin and its appendages – hairs and nails. Laboratory diagnosis. Problems in Medical Mycology. 2008;10(1):27–34. Available at: https://mycology.szgmu.ru/vypuski-zhurnala-problemy-meditsinskoj-mikologii.